Navigation Links
European cooperation ensures global leadership in microelectronics
Date:7/15/2010

Mass production of globally competitive electronics equipment relies heavily on the performance and availability of the latest microelectronics devices. The EUREKA MEDEA+ microelectronics Cluster FOREMOST project ensured that the advanced process modules and chip architectures required for full 45nm node CMOS logic and 50nm DRAM memory technologies are now being applied in European wafer-fabrication plants. This project enabled key European players in semiconductor manufacturing to develop these advanced technologies in line with market demands, thus safeguarding and boosting the position of Europe's chipmakers as well as their equipment and materials suppliers on the world stage. The 45nm technology developed in the first phase has already become the core process worldwide for mobile phone applications. Project results are also paving the way for future 32/28nm nodes.

There is constant pressure from the consumer electronics market, particularly in mobile devices, for ever smaller components offering ever greater performance while reducing power requirements. With global chip production moving fast to the 45nm node a measure of circuit detail Europe needed to ensure it could mass produce semiconductors to this new world standard.

Initial work had been carried out in the EU Sixth Framework Program (FP6) NANOCMOS project, which screened appropriate materials, device and interconnect architectures for 45 nm CMOS logic. Complementary metal-oxide-semiconductor (CMOS) technology is the dominant process for integrated circuit manufacture worldwide and is used in microprocessors, microcontrollers, memory devices and other digital logic circuits.

Strong support from national public authorities

FOREMOST was setup within EUREKA with strong support from the national public authorities in France, Germany and the Netherlands, among others. "We aimed at developing advanced process modules and transistors architectures, and integr
'/>"/>

Contact: Piotr Pogorzelski
piotr.pogorzelski@eurekanetwork.org
322-777-0979
EUREKA
Source:Eurekalert  

Page: 1 2 3 4

Related biology technology :

1. Shire Receives CHMP Positive Opinion for VPRIV(TM) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease in the European Union
2. Corgenix Receives Additional European Patent, Announces Publication of Important Clinical Study on AtherOx(R) Technology
3. ChemoCentryx Reports Positive Phase I Study Results for CCX354 at the Annual European Congress of Rheumatology (EULAR)
4. PRA International Exhibits at European Hematology Association Congress
5. Vermillion Announces Issuance of European Patent
6. Glycosan BioSystems Seeks CE Mark in the European Union for HyStem-Rx, a Unique, Implantable Scaffold for Tissue Engineering
7. Aeterna Zentaris Receives Positive Opinion for Orphan Medicinal Product Designation for AEZS-108 for the Treatment of Ovarian Cancer from the Committee for Orphan Medicinal Products of the European Medicines Agency
8. Soligenix Announces Grant of Broad European Patent for Topically Active Steroids to Treat Inflammatory Gastrointestinal Disorders
9. The European HEALTHGRAIN consortium developed a definition for whole grain
10. A number of European companies working together to create innovative facades with nanomaterials
11. European research initiative EUREKA presented at Research & Technology for the first time
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
European cooperation ensures global leadership in microelectronics
(Date:7/28/2014)... (PRWEB) July 28, 2014 Proove ... medicine, will be exhibiting data and research conducted through ... International Spine Intervention Society’s (ISIS) 22nd Annual Scientific ... at the Hyatt Regency, in Orlando, Florida. ... and clinical competence of physicians who care for patients ...
(Date:7/28/2014)... July 28, 2014 /PRNewswire/ -   JOLT , a ... companies to join its growing portfolio of startups. Next-level ... Toronto,s JOLT accelerator, and Cohort four ... roster. Since its launch in July ... raised  $7.5M of financing. Now at 23 investments, JOLT,s ...
(Date:7/28/2014)... 28, 2014  David Hardison, Ph.D., vice president ... , has been elected chairman of the board ... non-profit working to establish common protocols around the ... relates to electronic health records. ... collaborating with organizations across the research and health ...
(Date:7/28/2014)... , July 28, 2014   Propeller Health , ... announced the hire of Brad Towle as ... be responsible for driving the company,s sales growth, customer ... in healthcare, and specifically his past role in the ... the company at this pivotal time in the industry," ...
Breaking Biology Technology:Proove Biosciences Exhibits Industry Leading Data and Research at International Spine Intervention Society’s 22nd Annual Scientific Meeting 2JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 2JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 3ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 2ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 3Propeller Health Hires Brad Towle as Senior Vice President of Business and Client Development 2
... BRISBANE, Calif. , May 4 InterMune, Inc. (Nasdaq: ... issued a complete response letter for the New Drug Application (NDA) for ... to reduce decline in lung function. , ... A complete response letter is issued by the FDA,s Center ...
... Calif. , May 4 S*BIO Pte Ltd and Onyx ... development collaboration and option and license commercialization agreement for S*BIO,s novel JAK2 ... respectively. The expanded agreement builds upon the development and commercialization collaboration between ... , , ...
... Fla. , May 4 Romark Laboratories announced results ... of nitazoxanide in treatment-naive patients with genotype 1 chronic hepatitis C. ... a late breaking forum of the American Gastroenterological Association Institute (AGA ... . , , , ...
Cached Biology Technology:InterMune Receives FDA Complete Response Letter on Esbriet(TM) (Pirfenidone) New Drug Application 2InterMune Receives FDA Complete Response Letter on Esbriet(TM) (Pirfenidone) New Drug Application 3InterMune Receives FDA Complete Response Letter on Esbriet(TM) (Pirfenidone) New Drug Application 4InterMune Receives FDA Complete Response Letter on Esbriet(TM) (Pirfenidone) New Drug Application 5S*BIO and Onyx Pharmaceuticals Announce Expanded Development Collaboration for JAK2 Inhibitors 2S*BIO and Onyx Pharmaceuticals Announce Expanded Development Collaboration for JAK2 Inhibitors 3S*BIO and Onyx Pharmaceuticals Announce Expanded Development Collaboration for JAK2 Inhibitors 4S*BIO and Onyx Pharmaceuticals Announce Expanded Development Collaboration for JAK2 Inhibitors 5Romark Announces Final Data From Clinical Trial of Nitazoxanide in Treatment-Naive Patients With Genotype 1 Chronic Hepatitis C 2Romark Announces Final Data From Clinical Trial of Nitazoxanide in Treatment-Naive Patients With Genotype 1 Chronic Hepatitis C 3Romark Announces Final Data From Clinical Trial of Nitazoxanide in Treatment-Naive Patients With Genotype 1 Chronic Hepatitis C 4Romark Announces Final Data From Clinical Trial of Nitazoxanide in Treatment-Naive Patients With Genotype 1 Chronic Hepatitis C 5
(Date:7/27/2014)... have shown the potential for global climate change to ... most part, ignored the interactions between increasing temperature and ... to damage crops. , A new study involving researchers ... significant, suggesting that policymakers need to take both warming ... , The study looked in detail at global production ...
(Date:7/27/2014)... scientists have identified more than two dozen genetic ... that had not been previously reported. The study, ... funded by the National Institutes of Health (NIH) ... , "Unraveling the genetic underpinnings of Parkinson,s is ... this complex disease, and hopefully, may one day ...
(Date:7/25/2014)... burn scars on this false-color image from the Terra satellite ... year,s rash of wildfires in Eastern Russia. The burn ... green background. The wildfires have broken across the remote ... in this false-color image from the MODIS instrument, it ... fires that continue. Two recent image features noted below show ...
Breaking Biology News(10 mins):Study: Climate change and air pollution will combine to curb food supplies 2Study: Climate change and air pollution will combine to curb food supplies 3NIH scientists find 6 new genetic risk factors for Parkinson's 2
... A research team, led by Institute of Zoology ... reconstructed a continuous population history of the giant panda ... whereas global changes in climate were the primary drivers ... activities were likely to underlie recent population divergence and ...
... the IOF Regionals Asia-Pacific Osteoporosis Meeting, researchers from the ... Health, announced a study which links carotenoids to decreased ... who are lean (BMI In the study, ... and hip fracture risk across a range of BMI ...
... to crizotinib gaining approval for the treatment of advanced ... the United States, Canada, and several other countries in ... therapy for ALK-positive NSCLC places great emphasis on rapid, ... subtype of lung cancer. A recent study published in ...
Cached Biology News:Chinese scientists discover evidence of giant panda's population history and local adaptation 2Chinese scientists discover evidence of giant panda's population history and local adaptation 3Study shows immunohistochemistry is reliable screening tool for ALK rearrangement 2
Request Info...
Request Info...
Request Info...
Ready for formulation or direct injection into animals Provided in convenient 100, 250, 1000 and 10,000 nmol sizes HPLC purified, salt free, sterile filtered, and endotoxin tested ...
Biology Products: